Novartis’ Acquired RNA Therapeutic del-brax Achieves Phase 1/2 Success for Muscle-Wasting Diseases

June 28, 2026

BioPharma Dive USA

Overview

Novartis’ RNA therapeutic del-brax, acquired through its $12 billion purchase of Avidity Pharmaceuticals, successfully completed a Phase 1/2 clinical trial for muscle-wasting diseases, achieving its primary endpoints. This innovative Antisense Oligonucleotide Conjugate (AOC) modality demonstrates significant potential as a new treatment option for these debilitating conditions. The positive data marks a crucial milestone, bolstering Novartis’ rare disease pipeline and validating its strategic acquisition.

In Depth

Background

Muscle-wasting diseases represent a significant global health challenge, often genetically driven, incurable, and characterized by progressive muscle function loss that severely diminishes patients’ quality of life. Current therapeutic options remain limited, highlighting a substantial unmet medical need within this domain. Novartis has strategically intensified its investment in the rare disease sector, exemplified by its acquisition of Avidity Pharmaceuticals for an estimated $12 billion. RNA therapeutics, as a cutting-edge modality, have garnered considerable attention in recent years due to their broad target accessibility, enabling novel approaches to diseases previously intractable by traditional small-molecule drugs or antibody-based therapies.

Key Findings

Novartis’ investigational RNA therapeutic, del-brax, successfully achieved its primary endpoints in a recently concluded Phase 1/2 clinical trial targeting patients with muscle-wasting diseases. This positive outcome strongly indicates del-brax’s significant potential as a novel therapeutic option in an area with high unmet need. Del-brax leverages a next-generation RNA technology known as Antisense Oligonucleotide Conjugates (AOCs). AOCs function by binding to specific messenger RNA (mRNA) molecules, thereby modulating gene expression and inhibiting the production of disease-causing proteins. This innovative technology aims to enhance both target specificity and cellular drug delivery efficiency compared to conventional antisense oligonucleotides (ASOs). The Phase 1/2 trial rigorously assessed the drug’s safety, tolerability, and preliminary efficacy, reporting favorable results across all evaluated metrics.

Significance & Outlook

The successful completion of the del-brax Phase 1/2 trial provides robust support for advancing the therapeutic into further clinical development, particularly late-stage pivotal trials. Novartis aims to introduce this innovative RNA therapeutic to the market, with the goal of instigating a paradigm shift in the treatment landscape for muscle-wasting diseases. Beyond its direct impact, this success is anticipated to positively influence the broader trajectory of RNA therapeutic development, potentially accelerating investment and research into RNA-based medicines for a wide array of other disease indications.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.